Researchers will use machine learning to analyze anonymous eye scans, which they will then use to create an algorithm that can better spot early signs of eye conditions.
Diabetes can result in a common complication—known as diabetic retinopathy—that damages the back of the eye, known as the retina. The chronic disease can cause vision loss if left untreated. It’s one the leading causes of blindness in American adults.
But if caught early, patients can significantly reduce the risk of blindness. Google’s DeepMind, which specializes in artificial intelligence, is partnering with Britain’s National Health Service to do just that. NHS is Britain’s publicly funded health care system—free to use, treating a million patients every 36 hours and consisting of one of the largest workforces in the world.
“The NHS is a miracle,” says DeepMind’s co-founder Mustafa Suleyman. “Not because it’s perfect, but because it works as well as it does within some incredible constraints.”
Researchers will use machine learning to analyze anonymous eye scans, which they will then use to create an algorithm that can better spot early signs of eye conditions, such as diabetic retinopathy. The collaboration hopes to develop eye scans that increase both the speed and accuracy of diagnosis.
Suleyman told the Guardian: “If you have diabetes, you’re 25 times more likely to go blind. If we can detect this, and get in there as early as possible, then 98 percent of the most severe visual loss might be prevented.”
Earlier this year, DeepMind sent shock waves after beating a human player at the complex game of Go. The Alphabet-owned AI firm is keen to use the same technology to revolutionize healthcare, but has sparked controversy in the past.
This is the second collaboration between NHS and the tech giant. The first saw the development of a smartphone app that aimed to alert staff of patients at risk of kidney failure. The data-sharing agreement between NHS and DeepMind was heavily criticized as Google was given access to the health care data of up to 1.6 million patients.
Critics were concerned about the ways in which patient data would be shared and whether it would remain secure.